NMRA - NASDAQ
Neumora Therapeutics, Inc. Common Stock
$1.75
+0.11%Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
At a Glance
Live Snapshotnmra
Cash and Short Term Investments
Last Annual Value
182.53M
3-Year CAGR
-21%
5-Year CAGR
-1%
10-Year CAGR
%
Neumora Therapeutics, Inc. Common Stock Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 182.53M | -26.2% | -14.9% | N/A | |
 Alumis Inc. Common Stock NASDAQ:ALMS | 308.50M | 84.7% | N/A | N/A | |
 Prothena Corporation plc NASDAQ:PRTA | 307.53M | -20.8% | -11.9% | -2.3% | |
 RAPT Therapeutics, Inc. NASDAQ:RAPT | 231.06M | 13.3% | 4.0% | N/A | |
 Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | 96.23M | -17.3% | 2.1% | -12.0% | |
 Fulcrum Therapeutics, Inc. NASDAQ:FULC | 352.31M | 14.3% | 10.1% | N/A | |
 4D Molecular Therapeutics, Inc. NASDAQ:FDMT | 402.65M | 11.8% | 10.2% | N/A | |
 Omeros Corporation NASDAQ:OMER | 171.80M | -0.0% | 1.8% | 14.3% |
Neumora Therapeutics, Inc. Common Stock Fair Value Envelope
Related Guides
Continue your NMRA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.